Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/28/2024 | $8.00 | Buy | Rodman & Renshaw |
| 10/4/2021 | $6.00 | Buy | Mizuho |
| 9/14/2021 | $3.00 → $4.00 | Outperform | Raymond James |
CAMBRIDGE, Mass., Sept. 6, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the appointment of Richard L. Schilsky, MD, FASCO, FACP, FSCT to its Board of Directors, effective September 1, 2022. Dr. Schilsky brings over 40 years of experience in medicine and clinical research, specializing in new drug development and clinical trials for a wide range of cancers. "We are honored to welcome Dr. Schilsky, who brings a wealth of experience and deep knowledge to bolster Leap's drug development strategy," said Christopher Mirabelli, PhD, Chairman of Leap Therapeutics' Board. "He is a
8-K - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
10-Q - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
S-8 - LEAP THERAPEUTICS, INC. (0001509745) (Filer)
CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2024. Leap Highlights: Completed enrollment in the expanded randomized controlled Part B of the Phase 2 DeFianCe study evaluating DKN-01, Leap's anti-DKK1 monoclonal antibody, in combination with standard of care bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer (CRC); data expected in mid-2025Patient follow-up continuing in the randomized controlled Part C of the Phase 2 DisTinGuish study evaluating DKN-01 in
CAMBRIDGE, Mass., Sept. 30, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment of 188 patients has been completed in the randomized controlled Part B of the DeFianCe study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with standard of care bevacizumab and chemotherapy as a second-line treatment for patients with advanced colorectal cancer (CRC). "The completion of enrollment in Part B of the DeFianCe study marks a significant achievement and highlights the enthusiasm in the potential of DKN-01 from both patients and healthcare providers
CAMBRIDGE, Mass., Aug. 12, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2024. Leap Highlights: Overall response rate (ORR) increases to 33% across all evaluable patients and 38% across evaluable patients with left-sided CRC in updated data from Part A of the Phase 2 DeFianCe study evaluating DKN-01 in combination with bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer (CRC)Expanded the randomized controlled Part B of the DeFianCe study to 180 patients; enrollment expected to be comple
Rodman & Renshaw analyst Tony Butler initiates coverage on Leap Therapeutics (NASDAQ:LPTX) with a Buy rating and announces Price Target of $8.
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Leap Therapeutics (NASDAQ:LPTX) with a Buy and lowers the price target from $7 to $5.5.
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)
SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)
CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2024. Leap Highlights: Completed enrollment in the expanded randomized controlled Part B of the Phase 2 DeFianCe study evaluating DKN-01, Leap's anti-DKK1 monoclonal antibody, in combination with standard of care bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer (CRC); data expected in mid-2025Patient follow-up continuing in the randomized controlled Part C of the Phase 2 DisTinGuish study evaluating DKN-01 in
CAMBRIDGE, Mass., Aug. 12, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2024. Leap Highlights: Overall response rate (ORR) increases to 33% across all evaluable patients and 38% across evaluable patients with left-sided CRC in updated data from Part A of the Phase 2 DeFianCe study evaluating DKN-01 in combination with bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer (CRC)Expanded the randomized controlled Part B of the DeFianCe study to 180 patients; enrollment expected to be comple
CAMBRIDGE, Mass., May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2024. Leap Highlights: Completed $40 million private placement financing with participation from Gilead Sciences, Inc., a life sciences-focused investor, Samsara BioCapital, 683 Capital Partners, LP, Laurion Capital Management, and Rock Springs CapitalPresented clinical data from Part A of the Phase 2 DeFianCe study evaluating DKN-01 in combination with standard of care bevacizumab and chemotherapy in second-line patients with advanced colorectal ca
Rodman & Renshaw initiated coverage of Leap Therapeutics with a rating of Buy and set a new price target of $8.00
Mizuho initiated coverage of Leap Therapeutics with a rating of Buy and set a new price target of $6.00
Raymond James reiterated coverage of Leap Therapeutics with a rating of Outperform and set a new price target of $4.00 from $3.00 previously